Diabetic Kidney Diseases

Global Diabetic Kidney Diseases Market to Reach US$3.6 Billion by 2030

The global market for Diabetic Kidney Diseases estimated at US$2.9 Billion in the year 2024, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Angiotensin Receptor Blockers, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Calcium Channel Blockers segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$800.5 Million While China is Forecast to Grow at 6.2% CAGR

The Diabetic Kidney Diseases market in the U.S. is estimated at US$800.5 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$709.1 Million by the year 2030 trailing a CAGR of 6.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Diabetic Kidney Diseases Market – Key Trends & Drivers Summarized

Can Therapeutics Slow Down the Progression of Renal Decline?
Diabetic kidney disease (DKD), or diabetic nephropathy, is one of the most serious long-term complications of both Type 1 and Type 2 diabetes, accounting for nearly 50% of end-stage renal disease (ESRD) cases worldwide. With global diabetes prevalence rising, DKD has emerged as a significant healthcare burden, particularly in developed and aging populations. One of the most significant trends in this market is the shift from renin-angiotensin-aldosterone system (RAAS) inhibitors to newer classes of nephroprotective agents, including SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs), and GLP-1 receptor agonists.

Improved clinical guidelines are promoting earlier screening and multifactorial intervention, with an emphasis on not just glycemic control but also blood pressure management, proteinuria reduction, and cardiovascular risk minimization. Multidisciplinary management models involving nephrologists, endocrinologists, and cardiologists are reshaping treatment pathways to delay or prevent progression to dialysis or transplantation.

Why Is Drug Development Pivotal in Slowing DKD Progression?
Traditional therapies such as ACE inhibitors and ARBs have shown limited efficacy in halting disease progression, especially in advanced stages. The approval of SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) has been a game-changer, offering significant renal protection alongside cardiovascular benefits—even in patients without diabetes. Similarly, finerenone, a non-steroidal MRA, is demonstrating promising outcomes in reducing albuminuria and eGFR decline with a lower hyperkalemia risk.

Combination therapies using GLP-1 receptor agonists, SGLT2 inhibitors, and novel MRAs are becoming increasingly common in personalized DKD management. Additionally, anti-inflammatory and anti-fibrotic agents targeting the molecular mechanisms of renal injury are entering the late stages of clinical development. Diagnostic advancements like urine biomarkers and eGFR estimation tools are enabling earlier and more accurate disease staging.

Where Is the Market Expanding and Who Are the Target Populations?
The DKD market is growing fastest in regions with high diabetes prevalence and rapidly aging populations, including North America, China, and Western Europe. India and parts of Latin America are also emerging as hotspots due to high levels of undiagnosed diabetes and poor long-term glycemic control.

The market is heavily dominated by pharmaceutical companies offering integrated cardiorenal solutions, while diagnostic players are providing advanced testing panels for proteinuria, microalbuminuria, and serum creatinine. Key stakeholders also include public health agencies promoting kidney screening programs and value-based care models incentivizing long-term renal preservation.

What’s Driving Growth in the Diabetic Kidney Diseases Market?
The growth in the diabetic kidney diseases market is driven by multiple factors including rising global diabetes incidence, improved drug therapies, and early diagnostic capabilities. The introduction of SGLT2 inhibitors and non-steroidal MRAs is expanding treatment options with proven renal protection benefits. Growing investment in CKD clinical research and the emergence of novel anti-inflammatory agents are also fueling the innovation pipeline.

Increased awareness of DKD’s link to cardiovascular outcomes is enhancing diagnosis and treatment rates. Government health systems and private insurers are recognizing the cost savings of early intervention, thereby incentivizing use of advanced therapies. Together, these trends are transforming DKD from a poorly managed diabetes complication into a focal point of preventive nephrology.

SCOPE OF STUDY:

The report analyzes the Diabetic Kidney Diseases market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Class (Angiotensin Receptor Blockers, Calcium Channel Blockers, Antioxidant Inflammation Modulator, Angiotensin-Converting Enzyme Inhibitors, Other Drug Classes); Administration Route (Oral, Parenteral); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• AbbVie Inc.
• AstraZeneca plc
• Aurobindo Pharma Limited
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• CSL Vifor
• Daiichi Sankyo Co., Ltd.
• Dr. Reddy`s Laboratories Ltd
• Eli Lilly and Company
• Endo International plc
• F. Hoffmann-La Roche Ltd
• Fresenius Medical Care AG & Co. KGaA
• GlaxoSmithKline plc
• Inversago Pharma Inc.
• Johnson & Johnson
• Lexicon Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.